Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001367644-25-000124
Filing Date
2025-05-08
Accepted
2025-05-07 17:46:00
Documents
95
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ebs-20250331.htm   iXBRL 10-Q 1401934
2 EX-31.1 a311-papacert033125.htm EX-31.1 8498
3 EX-31.2 a312-lindahlcert033125.htm EX-31.2 8558
4 EX-32.1 a321-papacert033125.htm EX-32.1 3435
5 EX-32.2 a322-lindahlcert033125.htm EX-32.2 3385
11 ebs-20250331_g1.jpg GRAPHIC 75656
  Complete submission text file 0001367644-25-000124.txt   8248415

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250331.xsd EX-101.SCH 59886
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ebs-20250331_cal.xml EX-101.CAL 79673
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20250331_def.xml EX-101.DEF 321669
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250331_lab.xml EX-101.LAB 718677
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250331_pre.xml EX-101.PRE 537519
98 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250331_htm.xml XML 1111312
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33137 | Film No.: 25923086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)